Lisa Aziez

Lisa Aziez

Auto-generated profile, based on publicly available information

Lisa Aziez

Universite Paris Cite, INSERM, CNRS, Institut Cochin, Paris - France

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2026
Verified
Thesis
Closed access
LALisa Aziez
Lisa Aziez
La leucémie myéloïde aiguë (LAM) est un cancer hématologique agressif caractérisé par des résultats cliniques défavorables. Malgré les progrès des approches thérapeutiques telles que l'association du venetoclax, des inhibiteurs de FLT3 ou d'IDH1/2 à la chimiothérapie traditionnelle, de nombreux patients rechutent, ce qui souligne la nécessité d'améliorer les stratégies thérapeutiques. De nouvelles données suggèrent que les immunothérapies pourraient constituer une option prometteuse pour le traitement de la LAM. Dans cette étude, nous avons cherché à savoir si les patients atteints de LAM présentaient des réponses des cellules T spécifiques de la tumeur. Nous avons caractérisé les cellules T d'échantillons appariés de sang et de moelle osseuse (BM) de patients en utilisant la cytométrie de masse et le séquençage de TCR. De cette manière, nous avons identifié une population distincte de cellules T CD8+ spécifiques de la moelle osseuse (CD69+, PD-1+) présentant un profil transcriptionnel et cytokinique unique ainsi qu'une population non spécifique issue d'une contamination du sang. Le séquençage du TCR a révélé une expansion clonale au sein de cette population, suggérant une activation induite par l'antigène. Une première analyse de la spécificité antigénique par un criblage par le tétramère du CMH-I met en évidence la présence de lymphocytes T spécifique à des antigènes non liés au cancer (« bystander »). En conclusion, ces résultats fournissent une meilleure compréhension du paysage immunitaire dans les LAM au niveau phénotypique mais aussi fonctionnel.

19 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
NDNicolas Deredec
Nicolas Deredec
LALisa Aziez
Lisa Aziez
IBIsmael Boussaid
Ismael Boussaid
JDJustine Decroocq
Justine Decroocq
AGAxelle Guedon
Axelle Guedon
YSYannick Simoni
Yannick Simoni
The emergence of bispecific antibodies (BsAbs) targeting T cells (CD3+) and tumor plasma B cells (BCMA+) has provided a new therapeutic option for patients with relapsed/refractory multiple myeloma cancer. However, responses to CD3xBCMA BsAb therapy remain heterogeneous, and treatment is associated with frequent immune-related adverse events. Although baseline immune characteristics have been associated with clinical outcomes, little is known about the early immune dynamics induced by this therapy. Here, we investigated whether longitudinal clinical monitoring and high-dimensional profiling of blood circulating T cells could identify early biomarkers of response or toxicity during treatment. Our results indicate that all treated patients exhibit an early depletion of circulating T cells associated with T-cell activation within the first two weeks. Integration of clinical and immunological parameters using Factorial Analysis of Mixed Data (FAMD) identified immune features associated with treatment outcome. Responders had lower plasma soluble BCMA concentrations, fewer bone lesions, higher circulating lymphocyte counts at baseline. During the first days of treatment, responders exhibited a more pronounced increase in plasma CXCL10 levels, associated with a greater decrease in T lymphocyte counts. Overall, our findings suggest that integrating clinical and immune parameters measured during the first days of treatment may enable early patient stratification and support the development of a predictive score to identify patients with multiple myeloma who are most likely to benefit from CD3xBCMA BsAb therapy.

15 August 2025 in bioRxiv
Verified
Preprint
Open access
LALisa Aziez
Lisa Aziez
NDNicolas Deredec
Nicolas Deredec
IBIsmael Boussaid
Ismael Boussaid
CSCarolyn G. Shasha
Carolyn G. Shasha
RVRomain Vazquez
Romain Vazquez
YSYannick Simoni
Yannick Simoni
Acute myeloid leukemia (AML) is a heterogeneous group of blood malignancies with a 5-year survival rate below 30%, highlighting the urgent need for more effective therapeutic strategies. T cell-based immunotherapies have demonstrated remarkable success in solid tumors, yet the role of CD8 + T cells in AML remains unclear. In this study, we analyzed the composition, antigenic specificity, and function of CD8 + T cells in paired blood and bone marrow samples from AML patients. While we did not identify exhausted CD8 + T cells as seen in solid tumors, we observed a distinct population of functional CD69 + CD8 + T cells specifically enriched in the bone marrow. These cells primarily recognized non-tumor antigens, including epitopes derived from Epstein–Barr virus (EBV) and cytomegalovirus (CMV). Notably, this bystander CD8 + T cell population showed high expression of Granzyme K, a cytokine found in the bone marrow of AML patients. Granzyme K did not induce leukemic cell death but instead promoted the secretion of IL-8, a pro-inflammatory cytokine known to play a detrimental role in AML pathology. Rather than mounting an anti-tumor response, these CD8 + T cells contribute to a pro-inflammatory environment that may exacerbate AML progression and severity. These findings provide a rationale for exploring therapeutic strategies aimed at inhibiting pro-inflammatory CD8 + T cells and targeting Granzyme K activity in association with actual therapies. Graphical

8 July 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
CVCamille Vaganay
Camille Vaganay
FLFrank Ling
Frank Ling
LKLois M. Kelly
Lois M. Kelly
JCJuliette Charles
Juliette Charles
PMPaul-Arthur Meslin
Paul-Arthur Meslin
APAlexandre Puissant
Alexandre Puissant
Chemotherapy resistance in acute myeloid leukemia (AML) remains a major clinical challenge. Integration of multiomic profiling and in vivo functional genomics revealed splicing dysregulation as a determinant of chemoresistance in AML. We uncovered a network involving the splicing regulator SRRM1 and the CLK1/4 and PAK1 kinase families as vulnerabilities in chemoresistant AML cells. Both kinase families are hyperactivated in chemoresistant cells, promoting SRRM1 phosphorylation and altering its scaffolding function. We also identified a relapse-associated PAK1 variant, c.1429G>T p.(Ala 477 →Ser), that confers chemotherapy resistance. Combined PAK1 and CLK1/4 inhibition recapitulated the splicing changes induced by SRRM1 loss, preferentially targeting chemoresistant AML and enhancing chemotherapy efficacy in cell lines, primary cells, and mouse models. Last, we pinpointed MAP2K5 as a critical downstream effector because missplicing of exons 17 and 18 of MAP2K5 upon SRRM1 depletion sensitized cells to chemotherapy. Our findings highlight a therapeutic strategy to overcome AML relapse by targeting splicing dysregulation.